What Cronase Treats: Main Uses and Benefits

Cronase is used for the symptomatic relief of conditions characterized by both active allergic manifestations and significant nasal congestion. It is commonly applied in clinical settings marked by heightened symptom expression that interferes with daily comfort, primarily for adults and adolescents. The medication is relevant for easing symptoms associated with acute or episodic changes.

Therapeutic Focus and Symptom Relief

This medication is commonly used to manage groups of symptoms associated with seasonal allergic rhinitis (hay fever). This includes the management of allergic-driven symptoms that may become disruptive, such as frequent sneezing, watery eyes, a clear runny nose (rhinorrhea), and pruritus (itching) of the nose, throat, or roof of the mouth. The combination is particularly relevant in situations where symptoms cluster into patterns requiring dual supportive management, specifically when nasal stuffiness is a major source of distress. This provides supportive relief and assists with maintaining functional stability when symptoms become more noticeable.

Quick Fact: Use in Dual Symptom Patterns

The medicine is used when symptoms include both classic allergic signs (itching, sneezing) and significant nasal stuffiness, which often occur together during symptomatic periods.

Regulatory References

1. DailyMed Label Information from the NIH

The eligibility for Cronase (Loratadine/Pseudoephedrine combination) is strictly defined by regulatory authorities. The medicine is authorized for use by adults and adolescents 12 years of age and older. Safety and efficacy are not established in children younger than 12 years, and use is generally not recommended in patients 60 years and older due to increased risk.

Cronase is absolutely contraindicated for specific populations. These exclusions include patients with a documented hypersensitivity to either active component or any formulation ingredients, as well as those with Severe Hypertension or Severe Coronary Artery Disease. Use is also prohibited concurrently with, or within 14 days of stopping, a Monoamine Oxidase Inhibitor (MAOI).

Furthermore, regulatory documents specify conditional use for certain health statuses. Patients with Renal Insufficiency or Hepatic Impairment require restricted use due to altered drug clearance. Individuals with conditions like Diabetes Mellitus, Hyperthyroidism, Narrow-angle Glaucoma, or Prostatic Hypertrophy should exercise caution. Use is not recommended during breastfeeding as both active components pass into breast milk, and caution is advised regarding use during pregnancy.

Interactions with other medicines and products

The documented interaction profile for Cronase is structured around pharmacodynamic and pharmacokinetic constraints associated with its two components. A primary restriction is the contraindication with Monoamine Oxidase (MAO) Inhibitors, which carries a risk of hypertensive crisis due to pseudoephedrine’s sympathomimetic action. A mandatory timing separation rule is applied, and the medicine must not be administered concomitantly or within 14 days of stopping MAOI therapy. Co-administration with Ergot Derivatives is also officially contraindicated due to the documented risk of enhanced vasoconstriction.

The Loratadine component is involved in a pharmacokinetic interaction when combined with inhibitors of CYP3A4 and CYP2D6, such as Ketoconazole and Erythromycin, resulting in increased systemic exposure. Furthermore, the Pseudoephedrine component can reduce the therapeutic effect of certain Antihypertensive Agents (e.g., Beta-blockers) and may increase ectopic pacemaker activity when used with Digitalis. Absorption is officially modified by Antacids (increasing the rate of pseudoephedrine absorption) and Kaolin (decreasing it), while ingestion with food only slightly delays Loratadine absorption. Use is officially not recommended in the presence of severe hepatic or renal impairment due to the documented risk of component accumulation.

Cronase functions as a combination agent, utilizing two distinct pharmacological mechanisms. The Loratadine component acts as a selective inverse agonist at peripheral Histamine H1-receptors. Its binding stabilizes the inactive conformation of the receptor, shifting the equilibrium away from the constitutively active state. This molecular interaction leads to a decrease in intracellular calcium signaling, which typically follows G-protein coupled receptor activation and is implicated in downstream inflammatory cascades. The Pseudoephedrine component is a sympathomimetic amine that primarily acts as an agonist at alpha-adrenergic receptors, particularly on the vascular smooth muscle of the respiratory mucosa. Activation of these receptors induces vasoconstriction of arterioles in the nasal passages. This systemic physiological modulation reduces local blood volume, thereby decreasing capillary hydrostatic pressure and extravasation of fluid into the surrounding tissue.

How to Use Cronase: Official Administration Guidelines

Cronase is a fixed-dose combination of loratadine and pseudoephedrine sulfate supplied as an oral extended-release tablet. The official use of this medicine is dictated by specific procedures to ensure the controlled release of its active ingredients. The route of administration is strictly oral.

Standard Dosing Regimens and Frequency

Administration depends on the chosen formulation:

In all cases, the maximum prescribed dose must not be exceeded within a 24-hour period. The medicine is generally intended for short-term use, with treatment duration advised to be kept as brief as possible.

Required Administration Protocol

The extended-release nature of the tablet imposes specific procedural constraints. The tablet must be swallowed whole with a full glass of water. It is a critical procedural requirement that the tablet must not be divided, crushed, chewed, or dissolved; this ensures the sustained release mechanism functions correctly. Cronase may be taken without regard to mealtime.

Population-Specific Use

Cronase is approved for use in adults and adolescents 12 years of age and older at the standard adult dosing regimen. For patients with severe renal impairment, official labeling may advise a modification to the dosing frequency, such as reducing the 12-hour formulation to a once-daily intake.

Cronase (pancrelipase) is a regulated pancreatic enzyme product approved for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to conditions like cystic fibrosis, chronic pancreatitis, or pancreatectomy.

Pivotal Trial Findings

Clinical development for Cronase included multiple randomized, placebo-controlled, double-blind trials to establish its role in managing EPI. The primary measure of effectiveness in these studies was the Coefficient of Fat Absorption (CFA), which assesses how well the body digests and absorbs dietary fat.

• Chronic Pancreatitis and Pancreatectomy: In one pivotal trial involving adults with EPI due to chronic pancreatitis or pancreatectomy, the administration of Cronase was associated with a statistically significant mean improvement in CFA compared to the placebo group. The mean CFA for the Cronase group was observed to be approximately 20 percentage points higher than for the placebo group after seven days of treatment.
• Cystic Fibrosis (CF): A similar controlled study in adult and pediatric patients (ages 12 to 43 years) with EPI due to cystic fibrosis also reported a significant difference in CFA between the Cronase and placebo arms. This change suggests that the product helps in the digestion of dietary fat in this population.

Secondary Observations

Beyond the primary endpoint, clinical trials also collected data on other measures. Patients who received Cronase often experienced a decrease in daily stool frequency and showed a mean increase in body weight compared to their starting baseline. Improvements in other symptoms related to malabsorption, such as abdominal pain and flatulence, were also noted in the open-label extension phases of the studies. These secondary findings support the drug's role in helping patients manage the symptoms of EPI.

Safety Profile

Adverse events reported in the clinical trial setting for chronic pancreatitis or pancreatectomy patients included abdominal pain, hyperglycemia, and nasopharyngitis. For patients with cystic fibrosis, reported adverse reactions included vomiting, dizziness, and cough. Regulatory bodies caution that high doses of pancreatic enzyme products have been associated with fibrosing colonopathy, particularly in patients with cystic fibrosis.

Common questions about Cronase (FAQ)

Q: How long do the effects of Cronase last after taking a single dose?

The medication is manufactured as an extended-release tablet designed to provide relief for specific durations. These formulations are designed to align with the dosing frequency, meaning they are formulated to last for either 12 hours or 24 hours after a single dose.

Q: How quickly does Cronase typically start working after the first use?

Studies related to the active component loratadine have reported the onset of action for symptom relief to occur within a window of 75 to 180 minutes following administration. This data provides a general expectation for when the medicine begins to work.

Q: How long does Cronase usually stay in your system?

Regulatory pharmacokinetic data suggests that the active metabolite of one component (loratadine) has a half-life of approximately 28 hours. The half-life is a measure of the time it takes for the concentration of the substance in the body to be reduced by half. This period influences how long the substance remains present.

Q: What happens in general if a scheduled dose of Cronase is missed?

The regulatory guidance states that the missed dose should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the instruction is to skip the missed dose entirely. This protocol is intended to prevent accidentally taking a double dose.

Q: What are the signs of a serious allergic reaction to Cronase?

Official instructions state that immediate medical help should be sought if signs of a serious allergic reaction occur. These signs are described as potentially including swelling of the face, lips, tongue, or throat, or experiencing difficulty breathing. These are classified as serious events in the official safety information.

Q: Can Cronase affect my ability to drive or operate machinery?

Official labeling includes warnings that the medicine may cause effects such as blurred vision, dizziness, or impaired thinking and reactions. Caution is advised when driving or performing any other potentially hazardous activities. Official advice indicates that individuals should wait until they understand how the medicine affects them.

Q: Is Cronase safe to use while consuming alcohol?

Official warnings state that drinking alcohol has the potential to increase certain side effects associated with this medication. Individuals using this medicine should be aware of this potential interaction documented in the labeling.

Q: Does Cronase have a specific boxed warning from regulators?

Regulatory labeling for this combination product does not contain a specific FDA Boxed Warning. A Boxed Warning is the most prominent warning required by the FDA on prescription drug labeling when there are serious safety concerns.

Q: Is Cronase considered a controlled substance by regulatory bodies?

The official regulatory classification for this medication indicates that it is Not a controlled medication. This means it is not classified by the DEA (Drug Enforcement Administration) under the schedules for controlled substances.

Q: Is Cronase available as a generic medicine yet?

Official documentation indicates that this medicine has received Abbreviated New Drug Application (ANDA) status. This regulatory designation indicates that a generic version of the medicine is available on the market.

Q: Are there any specific foods or drinks officially recommended to avoid while taking Cronase?

Official product information suggests the medicine may generally be taken with or without food. Studies related to one component (loratadine) indicate that taking the tablet with a meal only slightly delays its absorption. Official information does not contain universal recommendations to avoid specific foods.

Q: Can I take Cronase with common non-prescription drugs like [e.g., ibuprofen or an antacid]?

Official regulatory documents note that Antacids can increase the absorption rate of the pseudoephedrine component. The regulatory information does not specifically list warnings for common, over-the-counter pain relievers like ibuprofen. The full interaction list in the official labeling describes known concerns.

Q: What kind of liver or kidney checks are sometimes required when using Cronase?

Official labeling advises that individuals with existing liver or kidney disease should seek advice from a health professional. This consultation is necessary because reduced drug clearance in these conditions may require adjustment of the dosing regimen. The decision on the appropriate dose modification is determined by the prescribing professional.

Q: Where can I read the official prescribing information for Cronase?

The complete official Prescribing Information (PI) is publicly available for general review. This document can be found on authoritative government drug information websites, such as the NIH DailyMed or the FDA drug database, by searching for the product or generic name.

Storage and Protection Requirements

Cronase (Loratadine and Pseudoephedrine Sulfate Extended-Release Tablets) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C.

The medication must be kept in its original container and protected from excessive moisture. It is required to keep the container tightly closed and store the product where it cannot be reached by children. The tablets must not be frozen.

Official Disposal Instructions

Disposal of unused or expired Cronase should follow federal guidelines. The preferred method is using an authorized drug take-back program. If this is unavailable, the unused medicine must be mixed with an undesirable substance, placed in a sealed container, and then discarded in the household trash. The tablets must not be flushed down the toilet.